Literature DB >> 8318471

Impairment of tritan colour vision after initiation of treatment with zidovudine in patients with HIV disease or AIDS.

S A Geier1, M Held, J R Bogner, U Kronawitter, T Berninger, V Klauss, F D Goebel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8318471      PMCID： PMC504513          DOI： 10.1136/bjo.77.5.315

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  10 in total

1.  Treatment of HIV infection--progress in perspective.

Authors:  L Corey; T R Fleming
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Visual dysfunction without retinitis in patients with acquired immunodeficiency syndrome.

Authors:  J I Quiceno; E Capparelli; A A Sadun; D Munguia; I Grant; A Listhaus; J Crapotta; B Lambert; W R Freeman
Journal:  Am J Ophthalmol       Date:  1992-01-15       Impact factor: 5.258

3.  Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.

Authors:  S M Whitcup; K M Butler; R Caruso; M D de Smet; B Rubin; R N Husson; J S Lopez; R Belfort; P A Pizzo; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1992-01-15       Impact factor: 5.258

Review 4.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

5.  Molecular basis of different forms of metachromatic leukodystrophy.

Authors:  A Polten; A L Fluharty; C B Fluharty; J Kappler; K von Figura; V Gieselmann
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

Review 6.  Acquired dyschromatopsias.

Authors:  W M Hart
Journal:  Surv Ophthalmol       Date:  1987 Jul-Aug       Impact factor: 6.048

7.  The effects on survival of early treatment of human immunodeficiency virus infection.

Authors:  N M Graham; S L Zeger; L P Park; S H Vermund; R Detels; C R Rinaldo; J P Phair
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

8.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Authors:  J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; G M Dickinson; G L Drusano; M J Egorin; W L George; F M Gordin
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
  10 in total
  4 in total

1.  Human retinal microglia express candidate receptors for HIV-1 infection.

Authors:  V T Pham; L Wen; P McCluskey; M C Madigan; P L Penfold
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

2.  Impairment of colour contrast sensitivity and neuroretinal dysfunction in patients with symptomatic HIV infection or AIDS.

Authors:  S A Geier; U Kronawitter; J R Bogner; G Hammel; T Berninger; V Klauss; F D Goebel
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

3.  Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.

Authors:  Andrea D Branch; Lea T Drye; Mark L Van Natta; Efe Sezgin; Sarah L Fishman; Douglas T Dieterich; Curtis L Meinert; Douglas A Jabs
Journal:  Clin Infect Dis       Date:  2013-09-30       Impact factor: 9.079

4.  A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.

Authors:  Comfort Kunak Ogar; Abiodun Abiola; Daniel Yuah; Ali Ibrahim; Ibrahim Adekunle Oreagba; Emmanuel C Amadi; Mojisola Christianah Adeyeye; Kazeem Adeola Oshikoya
Journal:  Pharmaceut Med       Date:  2019-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.